CD4 T cell stemness and inflammatory bowel disease

CD4 T 细胞干性与炎症性肠病

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Inflammatory bowel disease (IBD) is a chronic inflammatory disorder that results from a loss in intestinal homeostasis between the commensal microbiota and the immune system. Importantly, the etiology of IBD remains unknown, although numerous studies have demonstrated a central role for CD4 T cells in the induction of IBD. A tremendous amount of research has been performed to understand the functional aspects of the CD4 T cells that mediate the pathology and symptoms associated with IBD, and many of the currently approved therapies, as well as a number of treatments in clinical trials, target these properties. Still, there is not a cure for either Crohn’s Disease (CD) or Ulcerative Colitis (UC), and this may be in part because little is known regarding how pathogenic CD4 T cells perpetuate the chronicity of disease. In recent years, the importance of T cell stemness has emerged as a critical parameter that sustains protective and pathogenic cell mediated immunity. During chronic intestinal inflammation, we observe that effector CD4 T cells with stem-like properties are able to both sustain and confer disease and that these cells preferentially express ST6Gal-I-dependent α2-6 linked sialic acids on the cell surface. In addition, we find that ST6Gal-I sialylation of N-glycans is important for expression of the stemness-associated transcription factor, TCF1. These preliminary findings lead us to hypothesize that effector CD4 T cell stemness promotes and sustains chronic intestinal inflammation in both mice and humans, and that this intestinal inflammation in turn operates to preserve this unique population of T cells. Furthermore, we postulate that ST6Gal-I mediated sialylation is central to effector CD4 T cell stemness and the chronicity of disease. To test these hypotheses, we propose the following specific aims: Aim 1. Determine the impact of ST6Gal-I mediated sialylation on CD4 T cell driven intestinal inflammation and CD4 T cell stemness. Aim 2. Determine the effect of the inflammatory intestinal environment on CD4 T cell stemness. Aim 3. Determine the contribution of stem-like effector CD4 T cells to chronic intestinal inflammation. Collectively, these studies are designed to provide new information regarding how CD4 T cell stemness impacts the chronicity of IBD. Moreover, findings that result from this application will illustrate how the composition of the commensal microbiota, as well as post-translational modification of cell surface proteins, specifically N-glycan sialylation, regulates CD4 T cell pathogenicity and stemness during chronic intestinal inflammation.
项目总结/摘要 炎症性肠病(IBD)是一种慢性炎症性疾病,其由肠道炎症因子的损失引起。 体内微生物群和免疫系统之间的平衡。重要的是,IBD的病因 目前尚不清楚,尽管许多研究已经证明了CD 4 T细胞在诱导中的核心作用, IBD。已经进行了大量的研究来了解CD 4的功能方面, 介导IBD相关病理和症状的T细胞,以及许多目前批准的免疫调节剂, 治疗以及临床试验中的许多治疗以这些性质为目标。但仍然没有治愈的方法 克罗恩病(CD)或溃疡性结肠炎(UC),这可能部分是因为对 致病性CD 4 T细胞如何使疾病长期存在。近年来,T细胞的重要性 干性已经成为维持保护性和致病性细胞介导的免疫的关键参数。 在慢性肠道炎症期间,我们观察到具有干细胞样特性的效应CD 4 T细胞能够 这些细胞优先表达ST 6 Gal-I依赖性α2-6连接的唾液酸, 细胞表面的酸性物质。此外,我们发现N-聚糖的ST 6 Gal-I唾液酸化对于表达 干细胞相关转录因子TCF 1这些初步发现使我们假设, 效应CD 4 T细胞干细胞促进和维持小鼠和小鼠的慢性肠道炎症, 这种肠道炎症反过来又保护了这种独特的T细胞群, 细胞此外,我们推测ST 6 Gal-I介导的唾液酸化是效应CD 4 T细胞的中心, 以及疾病的慢性化。为了检验这些假设,我们提出了以下具体目标: 目标1。确定ST 6 Gal-I介导的唾液酸化对CD 4 T细胞驱动的肠道炎症的影响 和CD 4 T细胞干细胞。 目标二。确定炎症性肠道环境对CD 4 T细胞干细胞的影响。 目标3.确定干细胞样效应CD 4 T细胞对慢性肠道炎症的贡献。 总的来说,这些研究旨在提供关于CD 4 T细胞干细胞性 影响IBD的慢性化。此外,这项应用的结果将说明 肠道微生物群的组成,以及细胞表面蛋白的翻译后修饰, 特别是N-聚糖唾液酸化,调节慢性肠道疾病中CD 4 T细胞的致病性和干性。 炎症

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laurie Ellen Harrington其他文献

Laurie Ellen Harrington的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laurie Ellen Harrington', 18)}}的其他基金

CD4 T cell stemness and inflammatory bowel disease
CD4 T 细胞干性与炎症性肠病
  • 批准号:
    10404576
  • 财政年份:
    2020
  • 资助金额:
    $ 38.6万
  • 项目类别:
CD4 T cell stemness and inflammatory bowel disease
CD4 T 细胞干性与炎症性肠病
  • 批准号:
    10237294
  • 财政年份:
    2020
  • 资助金额:
    $ 38.6万
  • 项目类别:
CD4 T cell stemness and inflammatory bowel disease
CD4 T 细胞干性与炎症性肠病
  • 批准号:
    10624276
  • 财政年份:
    2020
  • 资助金额:
    $ 38.6万
  • 项目类别:
STAT4 regulation of effector CD4 T cells and CNS inflammation
STAT4对效应CD4 T细胞和中枢神经系统炎症的调节
  • 批准号:
    8885328
  • 财政年份:
    2015
  • 资助金额:
    $ 38.6万
  • 项目类别:
STAT4 regulation of effector CD4 T cells and CNS inflammation
STAT4对效应CD4 T细胞和中枢神经系统炎症的调节
  • 批准号:
    9033074
  • 财政年份:
    2015
  • 资助金额:
    $ 38.6万
  • 项目类别:
STAT4 regulation of effector CD4 T cells and CNS inflammation
STAT4对效应CD4 T细胞和中枢神经系统炎症的调节
  • 批准号:
    9452007
  • 财政年份:
    2015
  • 资助金额:
    $ 38.6万
  • 项目类别:
Regulation of effector CD4 T cell subsets during inflammatory bowel disease
炎症性肠病期间效应 CD4 T 细胞亚群的调节
  • 批准号:
    8448740
  • 财政年份:
    2010
  • 资助金额:
    $ 38.6万
  • 项目类别:
Regulation of effector CD4 T cell subsets during inflammatory bowel disease
炎症性肠病期间效应 CD4 T 细胞亚群的调节
  • 批准号:
    7884829
  • 财政年份:
    2010
  • 资助金额:
    $ 38.6万
  • 项目类别:
Regulation of effector CD4 T cell subsets during inflammatory bowel disease
炎症性肠病期间效应 CD4 T 细胞亚群的调节
  • 批准号:
    8638951
  • 财政年份:
    2010
  • 资助金额:
    $ 38.6万
  • 项目类别:
Regulation of effector CD4 T cell subsets during inflammatory bowel disease
炎症性肠病期间效应 CD4 T 细胞亚群的调节
  • 批准号:
    8245097
  • 财政年份:
    2010
  • 资助金额:
    $ 38.6万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了